Search Results - subject:"Venlafaxine"

A Critical Review of Model-Based Economic Studies of Depression: Modelling Techniques, Model Structure and Data Sources

Haji Ali Afzali, Hossein; Karnon, Jonathan; Gray, Jodi - In: PharmacoEconomics 30 (2012) 6, pp. 461-482

Depression is the most common mental health disorder and is recognized as a chronic disease characterized by multiple acute episodes/relapses. Although modelling techniques play an increasingly important role in the economic evaluation of depression interventions, comparatively little attention...

Persistent link: https://www.econbiz.de/10010548284

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

Vera-Llonch, Montserrat; Dukes, Ellen; Rejas, Javier; … - In: The European Journal of Health Economics 11 (2010) 1, pp. 35-44

Persistent link: https://www.econbiz.de/10009404192

Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany

Kulp, Werner; Schulenburg, J.-M.; Greiner, Wolfgang - In: The European Journal of Health Economics 6 (2005) 4, pp. 317-321

Persistent link: https://www.econbiz.de/10009404152

Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom

Guest, J.; Russ, J.; Lenox-Smith, A. - In: The European Journal of Health Economics 6 (2005) 2, pp. 136-145

Persistent link: https://www.econbiz.de/10009404282

Evaluation of the Cost Effectiveness of Escitalopram versus Venlafaxine XR in Major Depressive Disorder

Fernandez, Jose-Luis; Montgomery, Stuart; Francois, Clement - In: PharmacoEconomics 23 (2005) 2, pp. 155-167

Aim: To assess the relative cost effectiveness of escitalopram compared with venlafaxine XR in patients with major … clinical trial and examined the costs and quality of life of 251 patients taking escitalopram versus venlafaxine. Outpatients … fulfilling criteria for MDD were randomised to receive oral escitalopram 10-20 mg/day or venlafaxine 75-150 mg/day for 8 weeks …

Persistent link: https://www.econbiz.de/10004990327

Economic Considerations in the Prescribing of Third-Generation Antidepressants

Montgomery, Stuart; Doyle, John J.; Stern, Lee; … - In: PharmacoEconomics 23 (2005) 5, pp. 477-491

A comprehensive, multinational literature search was conducted of all articles published from 1993 to 2003 regarding the cost effectiveness of antidepressant drugs, with special emphasis on comparing third-generation antidepressants (TGAs) with tricyclic antidepressants (TCAs) and selective...

Persistent link: https://www.econbiz.de/10005404934

Remission from Depression: A Review of Venlafaxine Clinical and Economic Evidence

Han, Donald; Wang, Edward C.Y. - In: PharmacoEconomics 23 (2005) 6, pp. 567-581

death. Venlafaxine, a dual-acting serotonin norepinephrine (noradrenaline) reuptake inhibitor, may improve a patient … date, there are only a small number of economic studies of venlafaxine, and most are cost or resource utilisation analyses … with significant limitations. Nevertheless, two cost-effectiveness analyses of venlafaxine are available. They found …

Persistent link: https://www.econbiz.de/10005404970

Cost Effectiveness of Representatives of Three Classes of Antidepressants Used in Major Depression in the UK

Lenox-Smith, Alan; Conway, Pete; Knight, Chris - In: PharmacoEconomics 22 (2004) 5, pp. 311-319

(serotonin and noradrenaline reuptake inhibitors [SNRIs; venlafaxine], selective serotonin reuptake inhibitors [SSRIs; fluoxetine … effectiveness were then calculated. Main outcome measures and results: Treatment costs for 6 months were Lstg 1285 for venlafaxine … 21 for venlafaxine, Lstg 26 for SSRIs and Lstg 32 for TCAs (2001 values). Incremental cost-effectiveness analyses showed …

Persistent link: https://www.econbiz.de/10005404795

The Importance of Achieving Additional Drug Benefits at a Reasonable Cost: A Review of the Fluoxetine Years

Freemantle, Nick; Mason, James - In: PharmacoEconomics 17 (2000) 4, pp. 319-324

Fluoxetine continues to be remarkably successful; greater volumes of this drug are sold than for any other antidepressant in the world. Prozac(R) has also become a household name. In this article we examine the circumstances that surround this success, and the evidence base that supports it....

Persistent link: https://www.econbiz.de/10005243117

Mirtazapine: A Pharmacoeconomic Review of its Use in Depression

Holm, Kristin J.; Jarvis, Blair; Foster, Rachel H. - In: PharmacoEconomics 17 (2000) 5, pp. 515-534

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). The antidepressant efficacy of mirtazapine has been established in randomised, double-blind comparative studies. Mirtazapine has generally shown similar efficacy to other antidepressants. There is evidence for a...

Persistent link: https://www.econbiz.de/10005405002